John R. Walsh, M.D., F.A.C.P.; Robert E. Mass, M.D.; Frederic W. Smith, M.D.; Verna E. Lange, B.S.
This content is PDF only. Please click on the PDF icon to access.
Desferrioxamine (DF), an iron chelating substance, was given parenterally to four patients with idiopathic hemochromatosis, eight patients with cirrhosis of the liver associated with various degrees of iron stores, two patients with hemosiderosis related to blood transfusions, and two control patients. Control patients excreted insignificant amounts of iron in their urine (< 2.0 mg/24 hr), compared with patients with hemochromatosis and hemosiderosis (2.5 to 45 mg/24 hr). Clinical and pathological differentiation of idiopathic hemochromatosis from the hemosiderosis seen with Laennec's cirrhosis was difficult; some patients with the latter exhibited urinary iron excretion patterns similar to patients with hemochromatosis. Therefore, urinary
Walsh JR, Mass RE, Smith FW, et al. Iron Chelation with Desferrioxamine.. Ann Intern Med. 1964;60:728. doi: 10.7326/0003-4819-60-4-728_1
Download citation file:
Published: Ann Intern Med. 1964;60(4):728.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use